EMA recommends Moderna’s mCombriax — first flu/COVID combo on the table

The European Medicines Agency’s CHMP recommended Moderna’s mCombriax, a combined mRNA influenza and COVID‑19 vaccine for adults 50 and older. Moderna said the opinion reflects trial data showing antibody responses against both viruses; the decision now moves to the European Commission for final approval. The recommendation follows a difficult regulatory path in the U.S., where Moderna has faced additional data requests from the FDA.